// App-Quantinova.ai

: Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD

Researchers

Presenter

  • Mona Bafadhel

Principal Investigators

  • Dave Singh

  • Christine Jenkins

  • Stefan Peterson

  • Thomas Bengtsson

  • Peter Wessman

  • Malin Fagers

Medical Centers

  • Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,

  • Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, University of Manchester, Manchester, United Kingdom,

  • The George Institute for Global Health, The University of Sydney, Sydney, Australia

  • StatMind AB, Lund, Sweden.

  • AstraZeneca, Gothenburg, Sweden

Locations

  • United Kingdom

  • Australia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved